LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Merck & Co Inc.

Merck & Co Inc.

Suletud

SektorTervishoid

105.11 0.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

104.17

Max

105.36

Põhinäitajad
By Trading Economics
Sissetulek	1.4B 5.8B
Müük	1.5B 17B
P/E Sektori keskmine	13.262 76.798
Aktsiakasum	2.58
Dividenditootlus	3.22
Kasumimarginaal	33.497
Töötajad	73,000
EBITDA	1.7B 8.1B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+11.13% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.22% 2.37%
Järgmine dividendimakse kuupäev	8. jaan 2026

Turustatistika
By TradingEconomics
Turukapital	31B 250B
Eelmine avamishind	104.78
Eelmine sulgemishind	105.11

Uudiste sentiment

By Acuity

32%

68%

94 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

76.03 / 83.28 Toetus ja vastupanu

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 12:31 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal -- Update

14. nov 2025, 12:16 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

14. nov 2025, 11:20 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Cidara Shares Nearly Double Premarket on Report of Takeover by Merck

14. nov 2025, 11:11 UTC

Omandamised, ülevõtmised, äriostud

Merck Nears $9.2 Billion Deal for Cidara, FT Reports, Citing Sources

4. nov 2025, 13:03 UTC

Omandamised, ülevõtmised, äriostud

Merck Taking Full Control of MK-8690 Development Program

30. okt 2025, 10:45 UTC

Tulu

Merck 3Q Profit Rises on Strong Keytruda Demand

13. okt 2025, 12:19 UTC

Suurimad hinnamuutused turgudel

Bicara Shares Rise Premarket on FDA Breakthrough Designation

11. aug 2025, 12:43 UTC

Suurimad hinnamuutused turgudel

IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data

29. juuli 2025, 10:45 UTC

Tulu

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

26. nov 2025, 09:54 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Dell, HP, Workday -- WSJ

14. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. nov 2025, 13:19 UTC

Omandamised, ülevõtmised, äriostud

This Biotech Stock Is Soaring 100%. Merck Is Buying It. -- Barrons.com

14. nov 2025, 12:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pharma Sector Becoming Bidding Battlefield -- Market Talk

30. okt 2025, 13:49 UTC

Tulu

Merck Stock Falls. Sales of Key Products Missed Estimates. -- Barrons.com

30. okt 2025, 11:32 UTC

Tulu

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30. okt 2025, 10:51 UTC

Tulu

Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time. -- Barrons.com

30. okt 2025, 10:30 UTC

Tulu

Merck 3Q Keytruda Sales Up 10% >MRK

30. okt 2025, 10:30 UTC

Tulu

Merck 3Q Keytruda Sales $8.14B >MRK

7. okt 2025, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Merck Completes Acquisition Of Verona Pharma >MRK VRNA

29. juuli 2025, 11:13 UTC

Tulu

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29. juuli 2025, 10:45 UTC

Tulu

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29. juuli 2025, 10:30 UTC

Tulu

Merck: Updated FY Adj EPS Outlook Does Not Include Anticipated Impact of Verona Pharma Acquisition >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: $200M of Costs Related to Impact of Tariffs in FY Outlook Unchanged Vs Previous Guidance Pending Outcome of Additional Potential Government Actions >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: As Part of Initiative, Approved New Restructuring Program in Which Co. Expects to Eliminate Certain Administrative, Sales and R&D Positions >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Updated FY Adj EPS Outlook Includes Revised Negative Impact of Foreign Exchange of About 15c/Shr >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: For Latest 2Q, Recorded Charges of $649M Related to Restructuring Program >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck Narrows FY View To Sales $64.3B-$65.3B Vs Prior View $64.1B-$65.6B >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Expect Actions Under Restructuring Program to Result in Annual Cost Savings of About $1.7B, Which Will Be Substantially Realized by End of 2027 >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Will Continue to Hire Employees Into New Roles Across Strategic Growth Areas of the Business >MRK

29. juuli 2025, 10:30 UTC

Tulu

Merck: Restructuring Program Is Part of the Multiyear Optimization Initiative Expected to Achieve $3B in Annual Cost Savings by End of 2027 >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

11.13% tõus

12 kuu keskmine prognoos

Keskmine 116.38 USD 11.13%

Kõrge 139 USD

Madal 95 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Merck & Co Inc. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

76.03 / 83.28Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

94 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.